Advances in Management of Pain, Cancer, and Amyotrophic Lateral Sclerosis

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across disease management. Extracellular phosphorilation for pain management, biosimilar therapies for cancer, novel antibodies for immunotherapy, and stem cells for rare diseases are profiled. The corresponding clinical trial analysis is depicted along with industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies

Table of Contents

Advances in Management of Pain, Cancer, and Amyotrophic Lateral SclerosisInnovations in Management of Pain, Cancer, and NeurodegenerationTargeting Extracellular Phosphorylation for Pain ManagementBiosimilar Therapy for Non-squamous Non-small Cell Lung CancerNovel Bispecific Cancer ImmunotherapyLeveraging Mesenchymal Stromal Cells for Treating Amyotrophic Lateral SclerosisClinical Trial Analysis and Industry InteractionsClinical Trial AnalysisClinical Trial AnalysisIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.